secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2026-02-20T23:59:59+00:00
Accession:  0001493152-26-007598
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus prices $40M public offering of 9.76M shares at $4.10/share
-------------------------------------------------------------------

- Gross proceeds ~$40.0M from 9,756,100 shares at $4.10/share; net proceeds ~$37.0M (before over-allotment).
- Underwriters granted 30-day option to purchase up to 1,463,415 additional shares (15% of offering).
- Offering expected to close February 23, 2026; Lake Street Capital Markets sole book-runner.
- Net proceeds estimated at ~$42.64M if over-allotment fully exercised.
- Proceeds for general corporate purposes including working capital and G&A.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000149315226007598/0001493152-26-007598-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000149315226007598/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-007598

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer